Evidence map›Paper›PMID 34115261›Full record

ArticleClinical & experimental metastasis2021

CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells.

Mattias Lepsenyi, Nader Algethami, Amr A Al-Haidari, Anwar Algaber, Ingvar Syk, Milladur Rahman, Henrik Thorlacius

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Clinical & experimental metastasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Biomimetic nanotherapy forInternational journal of pharmaceutics: X · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Mechanisms of metastatic colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mattias LepsenyiSection of Surgery, Department of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, 20502, Malmö, Sweden.
Nader AlgethamiSection of Surgery, Department of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, 20502, Malmö, Sweden.
Amr A Al-HaidariSection of Surgery, Department of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, 20502, Malmö, Sweden.
Anwar AlgaberSection of Surgery, Department of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, 20502, Malmö, Sweden.
Ingvar SykSection of Surgery, Department of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, 20502, Malmö, Sweden.
Milladur RahmanSection of Surgery, Department of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, 20502, Malmö, Sweden.
Henrik ThorlaciusSection of Surgery, Department of Clinical Sciences, Malmö, Skåne University Hospital, Lund University, 20502, Malmö, Sweden. henrik.thorlacius@med.lu.se.
Lund University · SESkåne University Hospital · SE

Funding

Vetenskapsrådet 2017-01621
6 · The paper itself

Abstract

Peritoneal metastasis is an insidious aspect of colorectal cancer. The aim of the present study was to define mechanisms regulating colon cancer cell adhesion and spread to peritoneal wounds after abdominal surgery. Mice was laparotomized and injected intraperitoneally with CT-26 colon carcinoma cells and metastatic noduli in the peritoneal cavity was quantified after treatment with a CXCR2 antagonist or integrin-αV-antibody. CT-26 cells expressed cell surface chemokine receptors CXCR2, CXCR3, CXCR4 and CXCR5. Stimulation with the CXCR2 ligand, CXCL2, dose-dependently increased proliferation and migration of CT-26 cells in vitro. The CXCR2 antagonist, SB225002, dose-dependently decreased CXCL2-induced proliferation and migration of colon cancer cells in vitro. Intraperitoneal administration of CT-26 colon cancer cells resulted in wide-spread growth of metastatic nodules at the peritoneal surface of laparotomized animals. Laparotomy increased gene expression of CXCL2 at the incisional line. Pretreatment with CXCR2 antagonist reduced metastatic nodules by 70%. Moreover, stimulation with CXCL2 increased CT-26 cell adhesion to extracellular matrix (ECM) proteins in a CXCR2-dependent manner. CT-26 cells expressed the αV, β1 and β3 integrin subunits and immunoneutralization of αV abolished CXCL2-triggered adhesion of CT-26 to vitronectin, fibronectin and fibrinogen. Finally, inhibition of the αV integrin significantly attenuated the number of carcinomatosis nodules by 69% in laparotomized mice. These results were validated by use of the human colon cancer cell line HT-29 in vitro. Our data show that colon cancer cell adhesion and growth on peritoneal wound sites is mediated by a CXCL2-CXCR2 signaling axis and αV integrin-dependent adhesion to ECM proteins.

Indexed as

AnimalsChemokine CXCL2Colonic NeoplasmsExtracellular Matrix ProteinsHeterograftsHumansIntegrin alphaVMicePeritoneal NeoplasmsReceptors, Interleukin-8BSignal TransductionChemokine CXCL2CXCL2 protein, humanCXCR2 protein, humanExtracellular Matrix ProteinsIntegrin alphaVReceptors, Interleukin-8BChemokinesChemotaxisIntegrinsMetastasisPeritoneal carcinomatosis

Identifiers

PMID34115261
PMCPMC8318971
OpenAlexW3171735545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.